Life Changing Daily Pill that Fights Cancer and Autoimmune Diseases

Invest Now for a Limited Time

Trethera News

Gloved hand of a scientist in a lab writing on a digital stilus with a digital pen.

Blue DNA illustration

Photo of a series of test tubes.

Scientific microscope with visual representation of DNA helix

Trethera Receives $1.6 Million National Eye Institute Grant for Continued Advancement of TRE-515 Optic Neuritis Program

October 19, 2022

Trethera Announces Multiple Sclerosis Treatment Poster Presentation at the American Neurological Association Annual Meeting

October 4, 2022

U.S. Patent Office Issues Trethera Composition of Matter Patent Covering TRE-515, Extending Market Exclusivity to Late 2041

September 20, 2022

Trethera and UCLA Publish Data Demonstrating TRE-515 Ability to Control and Improve Multiple Sclerosis Symptoms in Mouse Models

September 7, 2022

Trethera Receives U.S. Patent Office Notice of Allowance Covering TRE-515 Structural Claims, Extending Protections to Late 2041

August 17, 2022